Sei Investments Co. Sells 10,165 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Sei Investments Co. lowered its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 3.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 263,582 shares of the biotechnology company’s stock after selling 10,165 shares during the quarter. Sei Investments Co. owned approximately 0.43% of Ascendis Pharma A/S worth $36,287,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its holdings in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after buying an additional 267,881 shares in the last quarter. American Century Companies Inc. grew its stake in Ascendis Pharma A/S by 17.5% during the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company’s stock valued at $56,072,000 after acquiring an additional 60,548 shares in the last quarter. Groupama Asset Managment bought a new stake in Ascendis Pharma A/S in the 3rd quarter valued at $60,000. ARS Investment Partners LLC lifted its stake in Ascendis Pharma A/S by 0.9% in the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock worth $36,549,000 after purchasing an additional 2,369 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in shares of Ascendis Pharma A/S by 14.0% during the 4th quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company’s stock valued at $28,151,000 after purchasing an additional 25,164 shares during the last quarter.

Analyst Ratings Changes

ASND has been the topic of a number of research analyst reports. Cantor Fitzgerald boosted their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 25th. UBS Group started coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 18th. Evercore ISI increased their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, February 18th. Finally, The Goldman Sachs Group boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $204.64.

Ascendis Pharma A/S Stock Performance

ASND opened at $167.99 on Tuesday. The stock’s 50 day moving average price is $142.05 and its 200-day moving average price is $136.15. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $169.37. The stock has a market cap of $10.20 billion, a price-to-earnings ratio of -23.66 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.